Hint mode is switched on Switch off
For swift navigation between sections

Quince Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Quince Therapeutics Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Quince Therapeutics Inc is developing treatments for Alzheimer's and other degenerative disorders.

Awards

News

26/06/2026 Quince Therapeutics: Material Modification To Rights Of Security Holders
17/05/2026 Quince Therapeutics: Entry Into A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Unregistered Sales Of Equity Securities, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Regulation Fd Disclosure, Financial Statements And Exhibits
17/05/2026 Quince Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
17/05/2026 Quince Therapeutics: Of The Original Report To Include The Audited Financial Statements Of Orphai As Of And For The Years Ended December31, 2025 And 2024 And The Unaudited Interim Condensed Consolidated Financial Statements Of Orphai As Of And For The Three Months Ended March31, 2026 And 2025; And (ii)update The Information In Item 9.01(b) Of The Original Report To Include The Unaudited Pro Forma Condensed Consolidated Financial Information Of The Company As Of And For The Three Months Ended March31, 2026 And The Year Ended December31, 2025. The Financial Statements Have Been Presented For Orphai, Which Was The Entity That Held All Of The Assets Acquired. None Of The Assets Acquired Were Attributable To Holdco. Additionally, This Amendment No.2 Is Filed To Incorporate By Reference Business And Risk Factor Information Of Orphai. This Amendment No.2 Does Not Amend Any Other Item Of The Original Report, Other Events
27/04/2026 Quince Therapeutics: Other Events
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001662774
  • EIN
    90-1024039
Registration is required to get access.